Synthesis, single-crystal and solution structure analysis and in vitro cytotoxic activity of two novel complexes of ruthenium(II) with in situ formed flavanone-based ligands.

被引:18
作者
Ochocki, Justyn [1 ]
Kasprzak, Maria [1 ]
Checinska, Lilianna [2 ]
Erxleben, Andrea [3 ]
Zyner, Elzbieta [1 ]
Szmigiero, Leszek [4 ]
Garza-Ortiz, Ariadna [5 ]
Reedijk, Jan [5 ]
机构
[1] Med Univ Lodz, Dept Bioinorgan Chem, PL-90151 Lodz, Poland
[2] Univ Lodz, Dept Crystallog & Crystal Chem, PL-90236 Lodz, Poland
[3] Natl Univ Ireland, Sch Chem, Galway, Ireland
[4] Med Univ Lodz, Dept Nucle Acids Biochem, PL-92215 Lodz, Poland
[5] Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands
关键词
BLADDER-CANCER; NAMI-A; ANTICANCER AGENT; ARENE COMPLEXES; INHIBITION; TUMOR; BINDING; KP1019; FFC14A; CELLS;
D O I
10.1039/c0dt00535e
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
Synthesis, structure and properties of two new flavanone complexes of Ru(II) are described. The new complexes form during the reaction of ruthenium(III) chloride with 3-aminoflavone (3-af) dissolved in an aliphatic alcohol. The formed products depend on the alcohol used and were found to be: cis-dichloridobis(3-imino-2-methoxyflavanone) ruthenium(II)center dot 3H(2)O (1) from a methanolic solution and cis-dichloridobis(3-imino-2-ethoxyflavanone)ruthenium(II)center dot 2H(2)O (2) from an ethanolic solution, in which the original ligand 3-af had been converted by dehydrogenative alcoholysis to an entirely new ligand. This paper presents the X-ray structure and detailed (1)H-NMR analysis of both new compounds, as well as the study of their antiproliferative activity. The coordination of Ru(II) is octahedral with [RuCl(2)N(2)O(2)] chromophores, having trans chlorides and common Ru-L distances. Both 1 and 2 are highly cytotoxic towards the cisplatin resistant EJ and L1210 cell lines, and both complexes are as active as cisplatin in the sensitive cell lines. They display the ability to overcome cisplatin resistance in the drug resistant sub-lines EJcisR and L1210R. The present evidence suggests that the mechanism of biological activity may be different for these ruthenium compounds compared to cisplatin.
引用
收藏
页码:9711 / 9718
页数:8
相关论文
共 33 条
[1]   In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].
Aird, RE ;
Cummings, J ;
Ritchie, AA ;
Muir, M ;
Morris, RE ;
Chen, H ;
Sadler, PJ ;
Jodrell, DI .
BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657
[2]   Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin [J].
Bergamo, A ;
Messori, L ;
Piccioli, F ;
Cocchietto, M ;
Sava, G .
INVESTIGATIONAL NEW DRUGS, 2003, 21 (04) :401-411
[3]   Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration [J].
Cocchietto, M ;
Zorzet, S ;
Sorc, A ;
Sava, G .
INVESTIGATIONAL NEW DRUGS, 2003, 21 (01) :55-62
[4]   GENERAL DEFINITION OF RING PUCKERING COORDINATES [J].
CREMER, D ;
POPLE, JA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1975, 97 (06) :1354-1358
[5]   ABSORPTION CORRECTION IN CRYSTAL STRUCTURE ANALYSIS [J].
DEMEULENAER, J ;
TOMPA, H .
ACTA CRYSTALLOGRAPHICA, 1965, 19 :1014-+
[6]   Photo-reduction of polyazaaromatic Ru(II) complexes by biomolecules and possible applications [J].
Elias, Benjamin ;
Kirsch-De Mesmaeker, Andree .
COORDINATION CHEMISTRY REVIEWS, 2006, 250 (13-14) :1627-1641
[7]   Synthesis, GC selective DNA binding and topoisomerase II inhibition activities of ruthenium(II) polypyridyl complex containing 11-aminopteridino [6,7-f][1,10]phenanthrolin-13(12H)-one [J].
Gao, Feng ;
Chao, Hui ;
Zhou, Feng ;
Chen, Xin ;
Wei, Yuan-Fang ;
Ji, Liang-Nian .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2008, 102 (5-6) :1050-1059
[8]   MONONUCLEAR AND DINUCLEAR RUTHENIUM COMPLEXES WITH TRIAZOLE-CONTAINING LIGANDS - FINE-TUNING OF THE SPECTROSCOPIC PROPERTIES [J].
HAGE, R ;
HAASNOOT, JG ;
REEDIJK, J ;
WANG, RY ;
VOS, JG .
INORGANIC CHEMISTRY, 1991, 30 (17) :3263-3269
[9]   From bench to bedside -: preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A) [J].
Hartinger, Christian G. ;
Zorbas-Seifried, Stefanie ;
Jakupec, Michael A. ;
Kynast, Bernd ;
Zorbas, Haralabos ;
Keppler, Bernhard K. .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2006, 100 (5-6) :891-904
[10]   The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells [J].
Kapitza, S ;
Jakupec, MA ;
Uhl, M ;
Keppler, BK ;
Marian, B .
CANCER LETTERS, 2005, 226 (02) :115-121